Monograph Details
|
|
Gastrointestinal Tract
> Hyperacidity, GERD, and ulcers
|
|
ZANTAC INJECTION |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
H2 blocker. |
| Generic Name |
|
Ranitidine (as HCl) 25mg/mL; IM or IV inj; contains phenol. |
| Also |
• ZANTAC
• ZANTAC EFFERDOSE
• ZANTAC INJECTION PREMIXED
• ZANTAC SYRUP
|
| Indications |
|
Hospitalized patients with pathological hypersecretory conditions, intractable duodenal ulcer. Short-term alternative to oral therapy. |
| Children |
|
<1month: not recommended. ≥1month–16yrs: Treatment of duodenal ulcer: 2–4mg/kg per day in divided doses every 6–8hrs; max 50mg every 6–8hrs. |
| Adults |
|
>16yrs: 50mg every 6–8 hrs by IM inj, or intermittent IV bolus (dilute; give over 5 min), or intermittent IV (dilute; give over 15–20 min); usual max 400mg/day. Continuous IV infusion, or for Zollinger-Ellison: see literature. Renal impairment (CrCl <50mL/min): 50mg every 18–24hrs or more often if needed (intermittent only). Coincide a dose for end of hemodialysis. |
| Precautions |
|
History of acute porphyria: not recommended. Renal impairment: reduce dose. Hepatic dysfunction. Discontinue if hepatic disorders occur. Monitor SGPT if on high-dose IV therapy for ≥5 days. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
May increase triazolam, midazolam, glipizide, procainamide levels. May decrease ketoconazole, atazanavir, delaviridine, gefitnib levels. Monitor anticoagulants. May cause false (+) urine protein test with Multistix. |
| Adverse Reactions |
|
Headache, GI disturbances, jaundice, hepatitis, rash; rare: CNS disturbances, arrhythmias, blurred vision, arthralgia, myalgia, inj site reactions, blood dyscrasias, anaphylaxis, angioneurotic edema, acute interstitial nephritis, bradycardia with rapid administration (IV); increased risk of pneumonia (see literature). |
| How Supplied |
Tabs 150mg—60, 180, 500
300mg—30
EFFERdose tabs—60
Syrup—pt
Inj single dose 2mL—10
Multidose 6mL—1
Premixed 50mL—24 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
